Media stories about La Jolla Pharmaceutical (NASDAQ:LJPC) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.840277157465 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
La Jolla Pharmaceutical (LJPC) traded down $0.75 during trading hours on Friday, hitting $36.83. 427,285 shares of the stock traded hands, compared to its average volume of 460,662. The company has a market cap of $815.60, a price-to-earnings ratio of -7.22 and a beta of 1.20. La Jolla Pharmaceutical has a 12 month low of $16.71 and a 12 month high of $41.36.
A number of research analysts have recently issued reports on LJPC shares. SunTrust Banks restated a “buy” rating and issued a $65.00 price target (down previously from $67.00) on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, November 1st. HC Wainwright boosted their price target on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Chardan Capital boosted their price target on shares of La Jolla Pharmaceutical from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Finally, BidaskClub downgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $58.57.
In other news, Director Laura L. Douglass sold 10,000 shares of La Jolla Pharmaceutical stock in a transaction on Friday, December 29th. The shares were sold at an average price of $32.32, for a total value of $323,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jennifer Carver acquired 1,000 shares of the stock in a transaction dated Wednesday, December 27th. The stock was bought at an average price of $33.22 per share, with a total value of $33,220.00. Following the purchase, the chief operating officer now directly owns 4,500 shares in the company, valued at $149,490. The disclosure for this purchase can be found here. Insiders own 25.47% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact La Jolla Pharmaceutical (LJPC) Share Price” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2018/02/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-la-jolla-pharmaceutical-ljpc-share-price.html.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.